LIFECARE ASA: KEY INFORMATION RELATING TO THE PROPOSED PARTIALLY UNDERWRITTEN RIGHTS ISSUE

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE.

Reference is made to the stock exchange announcement published by Lifecare ASA ("**Lifecare**" or the "**Company**") on 22 October 2025, regarding the proposal by the board of directors to increase the share capital of the Company through issuance of new shares in the Company (the "**New Shares**") through a partially underwritten rights issue with preferential subscription rights for existing shareholders (the "**Subscription Rights**"), raising gross proceeds of minimum NOK 80 million and up to NOK 100 million (the "**Rights Issue**"). Please see the following preliminary key information relating to the Rights Issue included below.

Date on which the terms and conditions of the Rights Issue were announced: 22 October 2025

Last day including right: 2 January 2026

Ex-date: 5 January 2026

Record Date: 6 January 2026

Date of approval: 2 January 2026 (extraordinary general meeting)

Maximum number of New Shares: To be announced when clarified

Subscription price: To be announced when clarified

Ratio preferential rights: To be announced when clarified

Subscription ratio: To be announced when the final number of New Shares has been determined

Managers: DNB Carnegie, a part of DNB Bank ASA, and SB1 Markets AS

Will the rights be listed: The Company will apply for trading of the Subscription Rights on Euronext Oslo Børs

ISIN for the preferential rights: To be announced when clarified

Other information: The subscription price for the New Shares to be issued in the Rights Issue, and thus the final number of New Shares and the exact amount of the share capital increase will be proposed by the board of directors, based on a recommendation from the managers, the day prior to the extraordinary general meeting to be held on or about 2 January 2026 (the "**Rights Issue EGM**"). Pursuant to the underwriting agreements for the Rights Issue, the subscription price in the Rights Issue shall be the theoretical share price exclusive of the Subscription Rights (TERP) based on the volume-weighted average price (VWAP) of the Company's shares on Euronext Oslo Børs the three trading days prior to the date of the Rights Issue EGM, less a discount of 35%. The board of directors' resolution in this respect will be announced through a stock exchange announcement on the day prior to the Rights Issue EGM and be reflected in the final proposed resolution to the Rights Issue EGM. See the stock exchange announcement published on 22 October 2025 for further information regarding the Rights Issue. The Rights Issue is subject to approval by the Rights Issue EGM.

Contacts

For further information, please contact:

Joacim Holter, CEO, Lifecare ASA, joacim.holter@lifecare.no, +47 400 59 040

Renete Kaarvik, CFO, Lifecare ASA, renete.kaarvik@lifecare.no, +47 948 38 242

Disclosure regulation

This information is published in accordance with the requirements of the Continuing Obligations for issuers listed on Euronext Oslo Børs.

About us

Lifecare ASA is a medical sensor company developing technology for sensing and monitoring of various body analytes. Lifecare's focus is to bring the next generation of Continuous Glucose Monitoring ("**CGM**") systems to market. Lifecare enables osmotic pressure as sensing principle. Lifecare's sensor technology is suitable for identifying and monitoring the occurrence of a wide range of analytes and molecules in the human body and in pets.